WOBURN, Mass., April 6, 2020 /PRNewswire-PRWeb/ -- Curiox
Biosystems in conjunction with STEMCELL Technologies today
announced a new system that will help researchers develop vaccines
to SARS-CoV-2, the virus that causes COVID-19.
A new configuration of the Laminar Wash™ HT1000 System will
allow scientists to completely process blood samples from COVID-19
positive patients in a safe environment. The package will consist
of an updated Laminar Wash HT1000 system, Buffer Exchanger, and
STEMCELL Technologies' EasySep™ RBC Depletion Reagent.
Laminar Wash technology enables researchers to more accurately
study immune responses for vaccine research and clinical trials
without the need for centrifugation, eliminating the aerosolization
of potentially infectious samples. Laminar Wash technology is
especially helpful in flow cytometry applications in vaccine
research. The new HT1000 configuration allows containment of blood
samples within a biosafety cabinet, ensuring the protection of
laboratory staff and other samples.
"We are always aspiring to help scientists perform their
research in a more accurate and safe manner" said Dr. Namyong Kim, CEO of Curiox Biosystems.
Traditionally, unwanted red blood cells (RBCs) are removed from
blood samples using lysis buffers, which can be harmful to white
blood cells, the cells responsible for immune response. By working
with STEMCELL Technologies' RBC depletion kits, researchers can
easily remove unwanted RBCs from blood samples without the need for
lysis, resulting in superior data quality.
"It is always a proud moment when the reagents and tools we
develop can help enable scientific discoveries and treatments. This
new application will facilitate the safe processing of blood
samples so that researchers can better understand the immune
response to current and future infectious disease outbreaks" said
Dr. Andy Kokaji, Director of
Immunology at STEMCELL Technologies.
Enabling safe and efficient handling of virus-positive blood
samples ultimately helps patients by accelerating treatment and
vaccine research. The new package of products is available
starting, March 23, 2020. Curiox and
STEMCELL Technologies are offering to assist institutions in
obtaining the product as easily as possible, with donations
considered in some cases.
About Curiox Biosystems
Curiox Biosystems is a bioinstrumentation company spun out of
the Agency for Science, Technology, and Research (A*STAR) in
Singapore. Curiox has become a
leader in the development and commercialization of innovative assay
platforms based on its expertise in surface chemistry and
engineering. Curiox's vision is to accelerate the progress of life
sciences, drug discovery and diagnostics through the
miniaturization and improved automation of bioassays.
About STEMCELL Technologies
STEMCELL Technologies is Canada's largest biotechnology company.
STEMCELL supports life sciences research with high-quality cell
culture media, cell separation technologies, instruments, accessory
products, and educational resources. STEMCELL's products are used
globally by scientists advancing the stem cell, immunology, cancer,
regenerative medicine, microbiology, and cellular therapy fields.
Find more information at http://www.stemcell.com
SOURCE Curiox Biosystems